Compare VRME & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRME | MBRX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 8.6M |
| IPO Year | N/A | 2016 |
| Metric | VRME | MBRX |
|---|---|---|
| Price | $0.63 | $3.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.50 | ★ $105.50 |
| AVG Volume (30 Days) | 443.8K | ★ 629.9K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,669,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $3.32 |
| 52 Week High | $5.00 | $91.25 |
| Indicator | VRME | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.67 | 47.57 |
| Support Level | $0.65 | $3.74 |
| Resistance Level | $0.67 | $4.24 |
| Average True Range (ATR) | 0.04 | 0.54 |
| MACD | 0.00 | -0.33 |
| Stochastic Oscillator | 4.40 | 4.78 |
VerifyMe Inc together with its subsidiaries, is a traceability and customer support services provider using specialized software and process technology. The company operates a Precision Logistics Segment and an Authentication Segment to provide specialized logistics for time-and-temperature sensitive products, as well as item-level traceability, anti-diversion and anti-counterfeit protection, brand protection and enhancement technology solutions. It Generates the majority of its revenue from the Precision Logistics Segment. Through its Precision Logistics segment, it provides a value-added service for sensitive parcel management driven by a proprietary software platform that provides predictive analytics from key metrics such as pre-shipment weather analysis, flight-tracking, and Others.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.